Stereochemistry | ABSOLUTE |
Molecular Formula | C28H30F2N6O8S |
Molecular Weight | 648.635 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)N2C=C(N=N2)C3=CC=CC(F)=C3)S[C@]4([H])O[C@H](CO)[C@H](O)[C@@H]([C@H]4O)N5C=C(N=N5)C6=CC=CC(F)=C6
InChI
InChIKey=YGIDGBAHDZEYMT-MQFIMZJJSA-N
InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1
TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 is formulated for inhalation, which enables direct targeting the fibrotic tissue in the lungs, while minimizing systemic exposure. TD139 was initially developed by a team of scientists from Lund University, Sweden, and Edinburgh University, the UK. TD-139 is in phase I/II clinical trials for the treatment of idiopathic pulmonary fibrosis.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
TD139 is delivered to the lungs of IPF patients using the Plastiape inhaler device at the following 3 doses: 0.3mg, 3mg, and 10mg.
Route of Administration:
Respiratory